dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Muñoz, Andrés |
dc.contributor.author | Jiménez-Castro, Jerónimo |
dc.contributor.author | Jimenez-Fonseca, Paula |
dc.contributor.author | Pericay, Carles |
dc.contributor.author | Longo-Muñoz, Federico |
dc.contributor.author | Argilés Martinez, Guillem |
dc.contributor.author | García-Alfonso, Pilar |
dc.date.accessioned | 2022-05-04T10:26:32Z |
dc.date.available | 2022-05-04T10:26:32Z |
dc.date.issued | 2021-09-08 |
dc.identifier.citation | García-Alfonso P, Muñoz A, Jiménez-Castro J, Jiménez-Fonseca P, Pericay C, Longo-Muñoz F, et al. Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study. Cancers. 2021 Sep 8;13(18):4514. |
dc.identifier.issn | 2072-6694 |
dc.identifier.uri | https://hdl.handle.net/11351/7475 |
dc.description | Quimioteràpia; Càncer colorectal; Trifluridina/tipiracil |
dc.description.sponsorship | This work was supported by the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) through a grant provided by Laboratorios Servier S.L. (grant reference number: not applicable). |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Cancers;13(18) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject | Còlon - Càncer - Tractament |
dc.subject | Recte - Càncer - Tractament |
dc.subject.mesh | Colorectal Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | Treatment Outcome |
dc.title | Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/cancers13184514 |
dc.subject.decs | neoplasias colorrectales |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | resultado del tratamiento |
dc.relation.publishversion | https://doi.org/10.3390/cancers13184514 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [García-Alfonso P, Muñoz A] Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. [Jiménez-Castro J] Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain. [Jiménez-Fonseca P] Department of Medical Oncology, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain. [Pericay C] Department of Medical Oncology, Hospital Universitari Parc Taulí, Sabadell, Spain. [Longo-Muñoz F] Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain. [Argilés-Martínez G] Servei d’oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 34572740 |
dc.identifier.wos | 000699174600001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |